Target Information

INVL Group has successfully concluded the initial closing of its second-generation private equity vehicle, the INVL Private Equity Fund II, raising €305 million. This amount exceeds the initial target of €250 million, establishing the fund as the largest private equity fund in the Baltic region. The fund's investment strategy is focused on countries including Lithuania, Latvia, Estonia, Poland, Romania, and the broader European Union. It aims to target companies that display strong growth potential.

Morphosis Capital has also launched its second fund, the Morphosis Capital Fund II, which has secured over €100 million in committed capital, effectively doubling the size of its previous fund. Based in Romania, this private equity firm intends to focus its investments on small and medium enterprises (SMEs) across Romania and surrounding regions, with particular attention to sectors such as healthcare, B2B services, consumer products, retail, and niche manufacturing.

Industry Overview in Romania

Romania’s private equity landscape has experienced significant growth in recent years, driven by increasing investor interest and a favorable business environment. The government has implemented reforms aimed at streamlining regulations and encouraging foreign investments, making it an attractive destination for private equity firms. Romanian SMEs are particularly appealing due to their potential for expansion and the overall improving economic climate.

The healthcare sector in Romania, where companies like Morphosis Capital are focusing their investments, is witnessing robust growth. Rising consumer demand for quality healthcare services combined with the ongoing digital transformation presents numerous opportunities for private equity investment. This sector benefits from governmental support, as health infrastructure continues to evolve.

Furthermore, the manufacturing sector in Romania has shown resilience, with many companies adapting to increased demand for innovative and niche products. The rise of tech-driven enterprises within this segment aligns with global trends, creating a dynamic investment environment that appeals to private equity investors seeking long-term returns.

Lastly, the retail and consumer products industries in Romania are also surging, fueled by a growing middle class and increased disposable income. As consumer preferences shift towards modern retail solutions, private equity firms are keen to invest in businesses that effectively cater to these emerging trends.

The Rationale Behind the Deal

The rationale for INVL Group's fundraising initiative lies in the increasing demand for private equity investment in the Baltic region, aimed at elevating the growth potential of budding companies. By establishing the INVL Private Equity Fund II, the firm positions itself to leverage the opportunities present in underserved markets across Central and Eastern Europe.

Similarly, Morphosis Capital's second fund launch is driven by the firm’s commitment to capitalize on the growth trajectory of Romanian SMEs. The fund's increased capital allows for larger investments, enabling diversification and the pursuit of more significant stakes in promising companies within critical sectors.

Investor Information

INVL Group is a recognized player in the Baltic private equity market, with a proven track record in managing assets and generating significant returns for its investors. Their expertise in identifying and nurturing high-potential investments positions them well to maximize performance through strategic partnerships and operational enhancements across portfolio companies.

Morphosis Capital, known for its focus on the Romanian market, continues to build its reputation by supporting SMEs in their growth journeys. Their commitment to developing the local ecosystem is evident through their targeted investment strategies, which aim to enhance value and drive sustainable business growth.

View of Dealert

The establishment of INVL Private Equity Fund II is a promising indicator of the Baltic region’s growing appeal among investors. The combination of substantial capital raised and a clear strategy to target high-growth potential companies suggests a strong likelihood of success. The fund’s diversified geographic and sectoral approach positions it well to take advantage of emerging opportunities across the EU, thus enhancing its long-term value proposition.

Morphosis Capital's second fund also appears to be a strategic move in an evolving market, especially with its firm focus on SMEs. The fund's emphasis on sectors like healthcare and niche manufacturing aligns with global demand trends, suggesting that it may present substantial growth opportunities and strong returns on investment.

Overall, the current landscape in the Baltic and Romanian markets signals favorable conditions for private equity investments. The array of opportunities available indicates that these funds are well-positioned not only to achieve their investment goals but also to contribute positively to the economic development of their respective regions.

View Original Article

Similar Deals

INVL Private Equity Fund II, IFC, Accession Capital Partners POLMED

2025

Other Private Equity Healthcare Providers & Services Poland
Enterprise Investors NZOZ Śródmieście-Biały Kamień

2024

Other Private Equity Healthcare Providers & Services Poland
... Scanmed

2024

Other Private Equity Healthcare Providers & Services Poland
Karo Healthcare Perrigo’s Dermacosmetics portfolio

2026

Buyout Healthcare Providers & Services Poland
ChristianaCare Crozer Health outpatient locations

2025

Other Private Equity Healthcare Providers & Services United States of America
HCAP Partners First Choice Mobile Radiology Services, LLC

2025

Other Private Equity Healthcare Providers & Services United States of America
Prime Healthcare Ascension facilities

2025

Other Private Equity Healthcare Providers & Services United States of America
Bain Capital HealthEdge and UST HealthProof

2025

Other Private Equity Healthcare Providers & Services United States of America
Zubr Capital amma

2025

Other Private Equity Healthcare Providers & Services Other
KKR Henry Schein

2025

Other Private Equity Healthcare Providers & Services United States of America

MidEuropa

invested in

Diagnostyka

in 2025

in a Other Private Equity deal

Disclosed details

Transaction Size: $441M

Revenue: $1M

EBITDA: $1M

EBIT: $1M

Net Income: $1M

Enterprise Value: $1M

Equity Value: $1M


Multiples

EV/EBITDA: 1.0x

EV/EBIT: 1.0x

EV/Revenue: 1.0x

P/E: 1.0x

P/Revenue: 1.0x

Deal Parametres
Industry
Country
Seller type

Sign Up to Dealert